Scientists Discover Hidden Switch That Helps Cancer Cells Evade Immune System
Scientists have uncovered a previously unrecognized transcription factor, HOXD13, that drives skin cancer growth while simultaneously suppressing the human immune system, according to a peer-reviewed study published in Cancer Discovery by researchers at NYU Langone Health and its Perlmutter Cancer Center. The molecule regulates gene activity to expand tumor blood supply while creating an immunosuppressive barrier that blocks cytotoxic T cells from attacking malignant tissue.
Key Clinical Takeaways:
- Researchers at NYU Langone Health identified transcription factor HOXD13 as a master switch driving melanoma progression and immune escape.
- HOXD13 increases tumor blood vessel formation via pathways like VEGF, while elevating adenosine levels to block T-cell infiltration.
- The findings point toward combination therapies targeting both angiogenesis and adenosine-receptor pathways in clinical settings.
Biological Mechanism of HOXD13 and Tumor Pathogenesis
Transcription factors govern how genetic instructions inside DNA convert into proteins. Per the study analyzing tumor samples from more than 200 melanoma patients across the United States, Brazil, and Mexico, elevated HOXD13 expression directly correlates with aggressive tumor behavior. The protein activates specific biological pathways responsible for angiogenesis—the creation of new blood vessels that deliver vital oxygen and nutrients to rapidly dividing cancer cells. These pathways include vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73.
When researchers experimentally reduced HOXD13 activity in laboratory models and human melanoma cell lines, tumors significantly decreased in size. Beyond driving vascularization, the protein reshapes the tumor microenvironment to construct an immune shield. According to the investigation, HOXD13 upregulation of CD73 increases local concentrations of adenosine. This chemical acts as a biochemical brake on the immune system, slowing down cytotoxic T cells and physically preventing them from infiltrating the cancerous mass.
“Our study provides new evidence that transcription factor HOXD13 is a potent driver of melanoma growth and that it suppresses the T cell activity needed to fight the disease,” explained Pietro Berico, PhD, a postdoctoral research fellow at the NYU Grossman School of Medicine and its Perlmutter Cancer Center, who served as the study’s lead investigator.
Patients with high HOXD13 levels exhibited fewer active T cells circulating in their blood and restricted immune cell penetration within their tumors.
Implications for Immunotherapy and Combination Clinical Trials
The discovery of this hidden switch bridges a critical gap in understanding why certain malignancies resist current standard-of-care immunotherapies. By identifying how tumors use metabolic barriers to evade detection, researchers can better design interventions that dismantle these defenses.
Eva Hernando-Monge, PhD, a professor in the Department of Pathology at the NYU Grossman School of Medicine and senior investigator on the study, pointed out that clinical trials are already actively evaluating pharmaceutical treatments that target adenosine receptors or VEGF in melanoma along with other types of cancer.
Some trials currently pair these receptor blockers with checkpoint inhibitors designed to unmask cancer cells to the immune system. If ongoing investigations yield positive outcomes, the research team plans to advance combination protocols targeting both angiogenesis and adenosine pathways specifically for patients exhibiting elevated HOXD13 expressions.
Furthermore, the research group intends to investigate whether these exact biological pathways operate in other malignancies characterized by high HOXD13 levels, including specific glioblastomas, sarcomas, and osteosarcomas. Funding for the study was provided by National Institutes of Health grants P30CA016087, R01CA274100, P50CA225450, and U54CA263001, alongside support from the Melanoma Research Foundation, the Melanoma Research Alliance, United Kingdom Medical Research Council grant MR/S01473X/1, and the Brazilian National Council for Scientific and Technological Development (CNPQ).
As combination trials progress toward later phases, monitoring patient response markers will help clarify precise contraindications and maximize therapeutic efficacy.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.